JAN Janus Living, Inc.

NYSE
$30.63

Janus Living, Inc. (JAN) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.6% since its last earnings release on August 4, 2026.

Janus Living Beat Consensus Estimates, Guides In-line
Tuesday, August 4, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:15 PM ET
Earnings Whisper
-
vs $0.24
Rev est $203.21M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $29.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Janus Living, Inc.

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

Sector

Financials

Industry

REIT – Residential